CASI PHARMACEUTICALS INC.
- Country
- 🇰🇾Cayman Islands
- Ownership
- Public
- Employees
- 243
- Market Cap
- $100.6M
Clinical Trials
22
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT07017725
- Locations
- 🇨🇳
North China University of Science and Technology Affiliated Hospital, TangShan, Hebei, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University, NanChang, Jiangxi, China
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04758767
- Locations
- 🇫🇷
CHU de Nantes - Hôpital Hôtel-Dieu, Nantes, France
🇫🇷CHU Rennes - Pontchaillou, Rennes, France
🇫🇷Gustave Roussy Cancer Center, Villejuif Cedex, France
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
- Conditions
- Advanced Fibrolamellar CarcinomaAdvanced Adult Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02234986
- Locations
- 🇺🇸
CASI Site 03, San Francisco, California, United States
🇺🇸CASI Site 04, Aurora, Colorado, United States
🇺🇸CASI Site 02, Boston, Massachusetts, United States
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01639248
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Inidiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇨🇳Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
- Conditions
- Peritoneal CancerFallopian CancerOvarian Cancer
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01104675
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next